

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

CRAWLEY, Karen
GlaxoSmithKline
Corporate Intellectual Property CN9
980 Great West Road
Brentford, Middlesex TW8 9GS
GRANDE BRETAGNE

Corporate IP	
Received: BRENTFORD	
16 MAR 2005	
ATTY: <u>KXC</u>	DATE: <u>30</u>
IPM: <u>N/A</u>	ON: <u>FILE</u>
ATTY CHECKED: <u>FILE</u>	

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year) 09.03.2005

Applicant's or agent's file reference
KXC/PG4890

IMPORTANT NOTIFICATION

International application No. PCT/EP 03/11813	International filing date (day/month/year) 22.10.2003	Priority date (day/month/year) 24.10.2002
---	---	---

Applicant
GLAXO GROUP LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk - Pays Bas
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl
Fax: +31 70 340 - 3016



Authorized Officer

Lafitte-de Jong, S

Tel. +31 70 340-4827



PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference KXC/PG4890	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA416)	
International application No. PCT/EP 03/1813	International filing date (<i>day/month/year</i>) 22.10.2003	Priority date (<i>day/month/year</i>) 24.10.2002
International Patent Classification (IPC) or both national classification and IPC C07D417/04		
Applicant GLAXO GROUP LIMITED et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		
Date of submission of the demand 05.05.2004	Date of completion of this report 09.03.2005	
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer Seitner, I Telephone No. +31 70 340-2389 	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/1813**

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-105 as originally filed

Claims, Numbers

1-23 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/11813**

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 13-15 (with respect to industrial applicability)

because:

- ☒ the said international application, or the said claims Nos. 13-15 relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the Standard.
☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-23
	No: Claims	
Inventive step (IS)	Yes: Claims	1-23
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-12, 16-23
	No: Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/11813

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 13-15 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: WO 01/85720 A (SMITHKLINE BEECHAM CORP ;CARR THOMAS (US);
DHANAK DASHYANT (US)) 15 November 2001 (2001-11-15)

D2: WO 00/09543 A (BOEHRINGER INGELHEIM CA LTD ;GOUDREAU
NATHALIE (CA); GHIRO ELISE () 24 February 2000 (2000-02-24)

D3: WO 99/54299 A (ABBOTT LAB) 28 October 1999 (1999-10-28)

D4: JOURNAL OF HETEROCYCLIC CHEMISTRY 1989, 26(4), 1023-1027

V.1. Novelty:

Document D1 discloses compounds (see examples 1-147; claims 2, 4) for the treatment of hepatitis C which differ in that the substituent corresponding to G represents C(=O)D, whereas in the present application G represents alkyl which cannot be substituted by oxo.

Document D4 discloses compounds (see examples 5, 8, and 10) which fall within the scope of the general formula (I) of claim 16 which is directed to their use as medicaments. The compounds of D4 have only been disclosed as chemical intermediates and no biological activity has been associated with said compounds.

Therefore, the subject-matter of claims 1-23 is novel over the prior art (Article 33(2) PCT).

V.2. Inventive Step:

Document D1, which is considered to represent the most relevant state of the art, discloses HCV inhibitors from which the subject-matter of present claim 1 differs in that the substituent G represents hydrogen or alkyl, whereas in D1 the pyrrole ring has to be substituted by C(=O)D in the 4-position.

The problem to be solved may therefore be regarded as the provision of further compounds for the treatment of viral infections.

Document D3 discloses a very general formula of compounds for the treatment of viral infections (see claims 1, 33-56) and especially influenza, which differ from the subject matter of the present application in that the group substituting the nitrogen atom of the pyrrolidine ring cannot be C(=O)D and the examples disclosed in D3 do not comprise a substituent corresponding to the present substituent J.

In view of the teaching of the prior art, the skilled person would not have had a clear incentive to combine the documents D1 and D3 and moreover, to focus on the 4-position of the pyrrolidine ring and to modify said position according to the present formula (I).

Therefore, the subject-matter of claims 1-23 is considered as involving an inventive step in the sense of Article 33(3) PCT.

V.3. Industrial Applicability:

The present application relates to compounds which are useful for the treatment of viral infections and the subject matter of claims 1-12, 16-23 is therefore considered as industrially applicable (Article 33(4) PCT).

For the assessment of the present claims 13-15 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known com-

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/11813

pound for first use in medical treatment and the use of such a compound for the
manufacture of a medicament for a new medical treatment.